Professor Dr Iris Loew-Friedrich MD, is Executive Vice-President Biopharma Development Solutions and Chief Medical Officer, UCB S.A. in Brussels. She is a member of the UCB Executive Committee and provides strategic global leadership for world-wide clinical development; medical affairs; global regulatory affairs and project leadership for UCB’s portfolio of pipeline projects and products. Iris Loew-Friedrich also oversees UCB’s Patient Affairs function, which places a strategic focus on better understanding and improving patient experience.
Iris Loew-Friedrich has held several medical and R&D roles, including Head of Global Projects at BASF Pharma (Ludwigshafen) and Therapeutic Area Head, Rheumatology and Bone Diseases, Hoechst/HMR (Bridgewater). From 2001, she served as a member of the Executive Board and as Head of Global Research and Development for Schwarz Pharma, which UCB acquired in 2006.
Iris Loew-Friedrich received her medical license and her PhD from Frankfurt University in 1985. She is board-certified in internal medicine and holds a professorship (‘außerordentliche Professur’) at Frankfurt University Medical School.